Processa Pharmaceuticals, Inc. Prepaid Expense and Other Assets, Current
Processa Pharmaceuticals, Inc. (PCSA) had Prepaid Expense and Other Assets, Current of $1.40 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › and Other Assets
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-14
- 2026-06-30: Prepaid Expense and Other Assets, Current $1.40M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $247.36K.
- 2025-12-31: Prepaid Expense and Other Assets, Current $133.92K.
- 2025-09-30: Prepaid Expense and Other Assets, Current $278.34K.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.40M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $247.36K 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $133.92K 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $278.34K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $217.20K 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $860.81K 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $687.83K 10-K · filed 2026-03-18 | $682.29K 10-K · filed 2025-03-20 |
| 2024-09-30 | $1.95M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $1.91M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $857.63K 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $926.30K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $1.05M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $1.22M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $1.48M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $1.88M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $1.83M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $1.90M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $1.99M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $1.76M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $1.51M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $1.66M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $1.42M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $554.71K 10-K · filed 2022-03-30 | |
| 2020-09-30 | $42.85K 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $97.68K 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $186.25K 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $315.61K 10-K · filed 2021-03-25 | |
| 2019-09-30 | $220.28K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $267.92K 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $247.20K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $257.83K 10-K · filed 2020-03-06 | |
| 2016-03-31 | $1.27K 10-Q · filed 2017-08-07 | |
| 2015-12-31 | $47.72K 10-K · filed 2017-09-25 | |
| 2015-09-30 | $5.97K 10-Q · filed 2015-12-01 | |
| 2015-06-30 | $32.50K 10-Q · filed 2015-08-19 | |
| 2015-03-31 | $42.43K 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $107.86K 10-K · filed 2017-06-19 | $131.86K 10-K · filed 2015-04-14 |
| 2014-09-30 | $117.35K 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $120.82K 10-Q · filed 2014-08-19 | |
| 2014-03-31 | $111.93K 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $80.39K 10-K · filed 2015-04-14 | |
| 2013-09-30 | $80.09K 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $48.46K 10-Q/A · filed 2013-09-06 | |
| 2012-12-31 | $56.37K 10-K · filed 2014-03-27 | $50.37K 10-Q/A · filed 2013-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |